U.S. markets closed

Beyond Air, Inc. (XAIR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9800-0.0700 (-3.41%)
At close: 04:00PM EST
2.0500 +0.07 (+3.54%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close2.0500
Bid1.7500 x 2200
Ask2.1500 x 800
Day's Range1.9300 - 2.0900
52 Week Range1.1700 - 7.1600
Avg. Volume470,109
Market Cap71.357M
Beta (5Y Monthly)-0.23
PE Ratio (TTM)N/A
EPS (TTM)-2.1300
Earnings DateFeb 07, 2024 - Feb 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for XAIR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Beyond Air, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/20/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

    Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to include cardiac surgery accepted for filing and under substantive review by the FDA U.S. pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway; trial will extend over two seasons; the pivotal study remains on track for Winter 2025/26 Phase 1 Study evaluating Beyond Cancer’s ultra-high concent

  • GlobeNewswire

    Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

    Call scheduled for Monday, February 12th at 4:30 pm Eastern TimeGARDEN CITY, N.Y., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), to

  • GlobeNewswire

    Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

    No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible patients in the next protocol defined cohort of 50,000 ppm in multiple centers in Israel HAMILTON, Bermuda, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) and a clinical stage biotechnology company developing ultra-high concentration nitric oxide